Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In diagnostic reagent services, domestic sales of materials for in vitro diagnostic pharmaceuticals, overseas sales of ELISA kits and sales of BSE kits increased. In transgenic silkworm services, sales of human collagen and antibodies increased. Meanwhile, testing services and the cosmetics-related business declined. Operating income in the antibody-related business increased due to higher sales of high-margin products.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥286 million (YoY +35.2%) |
| Operating profit | ¥117 million (YoY +116.5%) |
| Ordinary income | ¥120 million (YoY +108.7%) |
| Profit attributable to owners of the parent | ¥100 million (YoY +64.5%) |
| Net income per share | ¥10.76 |
| Equity ratio | End of the current fiscal period 84.8% / End of previous period 85.5% |
| Total assets | ¥2,226 million |
| Net assets | ¥1,887 million |
| Full-year earnings forecast | Net Sales ¥1,087 million (YoY +8.2%) / Operating profit ¥322 million (YoY +14.5%) / Ordinary income ¥322 million (YoY +7.1%) / Net income ¥347 million (YoY +5.5%) |
| Annual Dividend Forecast | ¥6.00 → ¥7.50（+25.0%） |
| Segment revenue | Segment Antibody-related business / Net Sales ¥285,471 thousand / yoy_pct ¥35.4 thousand, Segment Cosmetics-related business / Net Sales ¥536 thousand / yoy_pct ¥-19.5 thousand |
| Segment profit | Segment Antibody-related business / Segment profit ¥118,172 thousand / yoy_pct ¥116.2 thousand, Segment Cosmetics-related business / Segment profit ¥-398 thousand / yoy_pct Not disclosed |
| Depreciation and amortization | ¥4,474 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Loss on Investment Securities ¥11,847 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 0 companies (company name: —) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 9,314,590 shares |
| Treasury Shares at Period-End | 1,132 shares |
| Factors Behind Changes in Business Performance | In diagnostic reagent services, domestic sales of materials for in vitro diagnostic pharmaceuticals, overseas sales of ELISA kits and sales of BSE kits increased. In transgenic silkworm services, sales of human collagen and antibodies increased. Meanwhile, testing services and the cosmetics-related business declined. Operating income in the antibody-related business increased due to higher sales of high-margin products. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Domestic sales of materials for in vitro diagnostic pharmaceuticals, overseas sales of ELISA kits and sales of BSE kits increased, as did sales of human collagen and antibodies to major diagnostic reagent manufacturers. Operating income increased due to higher sales of high-margin products, while ordinary income increased mainly due to foreign exchange gains and other factors.